Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2001
10/04/2001WO2001072721A2 Synergistic methods and compositions for treating cancer
10/04/2001WO2001072720A1 Bicyclic amine derivatives as inhibitors of class 1 receptor tyrosine kinases
10/04/2001WO2001072718A1 Pharmaceutical compositions containing as the active ingredient nitropyrimidine derivatives or salts thereof
10/04/2001WO2001072717A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
10/04/2001WO2001072713A1 Non-steroidal, tetracyclic compounds for estrogen-related treatments
10/04/2001WO2001072711A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
10/04/2001WO2001072707A2 Carbamate caspase inhibitors and uses thereof
10/04/2001WO2001072703A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
10/04/2001WO2001072702A2 Amidino compounds useful as nitric oxide synthase inhibitors
10/04/2001WO2001072701A1 Ceramide derivatives and method of use
10/04/2001WO2001072699A1 Inhibition of angiogenesis and tumor growth
10/04/2001WO2001072692A1 Malonamic acids and derivatives thereof as thyroid receptor ligands
10/04/2001WO2001072685A2 Polyamine analogues as cytotoxic agents
10/04/2001WO2001072680A1 Substituted chalcones as therapeutic compounds
10/04/2001WO2001072341A2 Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
10/04/2001WO2001072336A1 Compounds for targeting
10/04/2001WO2001072333A1 Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2
10/04/2001WO2001072330A2 Method for immunostimulation using binding agents for the fc rec eptor of immunoglobulin a and for cancer cells or infections antigen
10/04/2001WO2001072329A1 Compositions and methods for enhancing immunogenicity of antigens
10/04/2001WO2001072328A2 Methods of treating diseases with activated protein c
10/04/2001WO2001072315A1 Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract
10/04/2001WO2001072301A1 Intracorporeal medicaments for photodynamic treatment of disease
10/04/2001WO2001072300A1 Uses of metal salts to stabilize taxane-based compositions
10/04/2001WO2001072299A1 Taxane-based compositions and methods of use
10/04/2001WO2001072297A1 Methods for inhibiting angiogenesis and tumor growth
10/04/2001WO2001072295A2 Compositions and methods for the therapy and diagnosis of lung cancer
10/04/2001WO2001072293A2 Antiprogestins with partial agonist activity
10/04/2001WO2001072281A2 Microspheres for active embolization
10/04/2001WO2001072279A2 Medical emulsion for lubrication and delivery of drugs
10/04/2001WO2001072277A2 Immunotherapeutic methods and compositions
10/04/2001WO2001049688A8 Purine derivatives, process for their preparation and use thereof
10/04/2001WO2001036638A8 Polypeptides and nucleic acids encoding same
10/04/2001WO2001036602A3 Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same
10/04/2001WO2001035989A3 Use of anti-idiotypical antibodies as vaccines against cancer
10/04/2001WO2001032685A3 Gene expression directed by a super-psa promoter
10/04/2001WO2001022990A3 Methods related to immunostimulatory nucleic acid-induced interferon
10/04/2001WO2001019828A3 Kinase inhibitors as therapeutic agents
10/04/2001WO2001019361A3 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate
10/04/2001WO2001013957A3 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
10/04/2001WO2001000244A3 METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
10/04/2001WO2000071564A8 Isolated nucleic acids of the p-hyde family, p-hyde proteins, and methods of inducing susceptibility to induction of cell death in cancer
10/04/2001WO2000053231A3 Fatty acid-anticancer conjugates and uses thereof
10/04/2001WO2000047625A9 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
10/04/2001WO1999061428A9 Quinazolines for treating brain tumor
10/04/2001US20010027216 Method for preventing hormone induced adverse effects
10/04/2001US20010027212 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
10/04/2001US20010027211 Anticarcinogenic, -inflammatory and -proliferative agents; viricides; bactericides; vascular restenosis, autoimmune diseases; psoriasis; anticolesterol and -lipemic agents
10/04/2001US20010027210 Administering a synergistic mixture of a compound of the xanthenone acetic acid class (5,6-dimethylxanthenone-4-acetic acid) and either paclitaxel or docetaxel; antitumor and -carcinogenic agents
10/04/2001US20010027207 Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation; anticarcinogenic, -diabetic, -proliferative and -inflammatory agents; vascular system disorders
10/04/2001US20010027202 Antitumor and -carcinogenic agents; solid cancers, e.g carcinomas of the lungs, pancreas, thyroid, bladder or color, myeloid disorders, e.g. leukemia or adenomas, e.g villous colon adenoma
10/04/2001US20010027197 Antiproliverative, -carcinogenic and -tumor agents; mitogenesis-activated protein kinase inhibitors; noncytotoxic; binding with high affinity at the adenosine triphosphate binding site of the kinases
10/04/2001US20010027195 Indeno [1,2-c]pyrazol-4-ones and their uses
10/04/2001US20010027184 Serine/threonine protein kinase (H-SGK2)
10/04/2001US20010027176 Cyclooxygenase inhibitor
10/04/2001US20010026932 Agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells; may be useful as antitumor agents
10/04/2001US20010026794 Two heterologous DNA encoding gene products; prolonged half-life
10/04/2001EP1138774A2 Defective recombinant adenoviruses expressing cytokines for use in antitumoral treatement
10/04/2001EP1138692A1 Fragments of human chorionic gonadotropin (hcg) as immunoregulator
10/04/2001EP1138680A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
10/04/2001EP1138673A2 Novel carbamates and ureas as modifiers of multi-drug resistance
10/04/2001EP1138326A1 Use of synthetic triglycerides based on conjugated linoleic acid in the preparation of agents for the treatment of catabolic conditions
10/04/2001EP1138325A1 Use of synthetic triglycerides based on conjugated linoleic acid in the preparation of agents aiding tumour treatment
10/04/2001EP1137946A1 Use of vascular endothelial growth factor (vegf)
10/04/2001EP1137792A1 A recombinant vector expressing multiple costimulatory molecules and uses thereof
10/04/2001EP1137783A2 Beta-1,3-galactosyltransferase homologs
10/04/2001EP1137780A1 Therapeutic and diagnostic uses of protein tyrosine phosphatase tc-ptp
10/04/2001EP1137779A2 Identification of senv genotypes
10/04/2001EP1137775A1 htfIIIA HUMAN GENE AND CODED hTFIIIA PROTEIN
10/04/2001EP1137773A2 Growth factor homolog zvegf3
10/04/2001EP1137769A1 T cells specific for target antigens and methods and vaccines based thereon
10/04/2001EP1137764A1 New medical use of gene and vector encoding a multisubstrate deoxyribonucleosidase
10/04/2001EP1137671A1 Reaction products of hyaluronic acid and natural amino acids and their use in cosmetic and pharmaceutical compositions
10/04/2001EP1137665A1 Cark protein and nucleic acid molecules and uses therefor
10/04/2001EP1137664A2 Protein transduction system and methods of use thereof
10/04/2001EP1137659A1 Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof
10/04/2001EP1137658A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES
10/04/2001EP1137656A1 31 human secreted proteins
10/04/2001EP1137642A1 Bis-sulfonamides
10/04/2001EP1137640A1 Cyclic hydrazine derivatives as tnf-alpha inhibitors
10/04/2001EP1137441A1 Ion exchange tumor targeting (iett)
10/04/2001EP1137439A2 Stabilization of macrolides
10/04/2001EP1137438A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors
10/04/2001EP1137436A1 Stimulation of t cells against self antigens using ctla-4 blocking agents
10/04/2001EP1137434A2 New cancer treatments
10/04/2001EP1137433A2 Pharmaceutical compositions containing protein-disulfide isomerases
10/04/2001EP1137427A1 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
10/04/2001EP1137426A1 Cancer treatment composition and method using natural plant essential oils
10/04/2001EP1137425A1 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils
10/04/2001EP1137422A2 Use of human prostate cell lines in cancer treatment
10/04/2001EP1137418A2 METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
10/04/2001EP1137415A1 Myt1 kinase inhibitors
10/04/2001EP1137411A1 Palladium-substituted bacteriochlorophyll derivatives and use thereof
10/04/2001EP1137410A1 Novel 4-dedimethy laminotetra cycline derivatives
10/04/2001EP1137402A1 Phospholipid compositions
10/04/2001EP1137400A1 Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period toff, verfahren zu seiner herstellung und anlage zur durchfuhrung des verfahrens
10/04/2001EP0981350B1 Use of 9,10-secocholesta-5,7,10(19)-triene-1,3-diol, or alfacalcidol
10/04/2001EP0891326B1 Novel vitamin d analogues
10/04/2001EP0853614B1 Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
10/04/2001EP0828726B1 Tricyclic inhibitors of matrix metalloproteinases
10/04/2001EP0821691A4 Methods of synthesizing gm2
1 ... 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 ... 2211